{"result": "(\"entity\"<|>TIROIDES<|>GEO<|>Tiroides refers to the thyroid gland, which is involved in the production of hormones and is the site of medullary thyroid carcinoma.)\n##\n(\"entity\"<|>FEOCROMOCITOMA<|>EVENT<|>Feocromocitoma is a type of tumor that can produce catecholamines and is important to rule out before surgery for medullary thyroid carcinoma.)\n##\n(\"entity\"<|>PET 18F-FDG<|>EVENT<|>PET 18F-FDG is a type of imaging study that is used to detect metastases in patients with medullary thyroid carcinoma.)\n##\n(\"relationship\"<|>MEDULLARY THYROID CARCINOMA<|>FEOCROMOCITOMA<|>Feocromocitoma must be ruled out before surgery for medullary thyroid carcinoma due to potential complications<|>8)\n##\n(\"relationship\"<|>MEDULLARY THYROID CARCINOMA<|>PET 18F-FDG<|>PET 18F-FDG is used to assess the presence of metastases in patients diagnosed with medullary thyroid carcinoma<|>6)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ía considerarse\" realizar linfadenectomía del compartimento contralateral (opción D correcta).\n\nReferencias:\n- Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab. 2010;95:2655-63.\n- Wells SA, Asa SL, Dralle H, Elisei R, Evan DB, Gagel RF, N, et al. Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. The American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Thyroid. 2015;25(6):567-610.\n\n## 50. Siguiendo con el caso anterior, si los niveles de calcitonina fuesen superiores a 500 pg/ml, nuestra actitud sería:\n\nA. No modificaría la actitud.\nB. Precisa que se realicen otros estudios morfológicos (TAC, etc.) para valorar la extensión de la enfermedad antes de la intervención.\nC. Determinaría que la cirugía tendría que ser más agresiva.\nD. Precisa tratamiento con radioterapia de forma inmediata tras la intervención.\n\n### COMENTARIO\n\nComo se ha expuesto en la pregunta anterior, los niveles preoperatorios de calcitonina ayudan a predecir la extensión de la enfermedad. Niveles superiores a 500 pg/ml se asocian con enfermedad metastásica o afectación ganglionar del mediastino superior, por lo que las guías ATA 2015 recomiendan realizar estudios radiológicos más extensos para excluir esta posibilidad (opción B correcta).\n\nReferencias:\n- Wells SA, Asa SL, Dralle H, Elisei R, Evan DB, Gagel RF, et al. Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. The American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Thyroid. 2015;25(6):567-610.\n\n## 3.8 Casos clínicos. Caso clínico 3\n\n### 51. Aunque los niveles de calcitonina plasmática orientarían hacia el diagnóstico, ¿en qué otras circunstancias pueden estar aumentados? (indique la respuesta falsa):\n\nA. Insuficiencia renal.\nB. Tratamiento con betabloqueantes.\nC. Hipergastrinemia.\nD. A y C son causas de elevación de la calcitonina.\n\n### COMENTARIO\n\nLa calcitonina (CT) es un péptido de 32 aminoácidos, segregado por las células parafoliculares del tiroides, que puede ser utilizado como marcador tumoral para el diagnóstico y seguimiento de los carcinomas medulares de tiroides.\n\nExiste amplia controversia en la literatura científica acerca de su utilidad en el protocolo diagnóstico de los nódulos tiroideos, controversia no resuelta en la actualidad. Una de las dificultades para su utilización sistemática en la valoración de los nódulos tiroideos es que la CT puede estar elevada no solo en los carcinomas medulares de tiroides, sino en muchas otras patologías: insuficiencia renal crónica, mastocitosis, tiroiditis linfocitarias, tumores neuroendocrinos, hipergastrinemia, cáncer prostático, etc.\n\nDe lo anteriormente expuesto se deduce que las opciones A y C son ciertas, ya que en ambas circunstancias la CT puede estar aumentada.\n\nEn cuanto a la opción B, es falsa, ya que no se ha descrito que el tratamiento con betabloqueantes pueda elevar la CT.\n\nReferencias:\n- Toledo SPA, Lourenço DM Jr, Santos MA, Tavares MR, Toledo RA, Correia-Deur JE. Hypercalcitonemia is not pathognomonic of medullary thyroid carcinoma. Clinics (Sao Paulo). 2009;64:699-706.\n---\n# TIROIDES 3\n\n## 52 Si se sospecha previamente un cáncer medular tiroideo, señale la respuesta falsa respecto a la cirugía:\n\nA. Debe descartarse previamente un feocromocitoma.\nB. Es conveniente estudios de extensión por frecuentes metástasis a distancia al diagnóstico.\nC. La sensibilidad de la PET 18F-FDG es del 98% aun con niveles muy bajos de calcitonina.\nD. La RMN generalmente es superior a otras pruebas de imagen para las metástasis óseas.\n\n### COMENTARIO\n\nCuando se diagnostica un cáncer medular de tiroides hay que descartar la posibilidad de que esté incluido dentro de un MEN2 y pueda albergar un feocromocitoma. Es importante descartar su presencia dado que podrían presentarse crisis hipertensivas durante la anestesia o el acto quirúrgico, por lo que la Guía ATA 2015 para el manejo del cáncer medular de tiroides recomienda su detección antes de la cirugía (opción A cierta).\n\nIgualmente se puede considerar cierta la opción B. A\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>AMERICAN THYROID ASSOCIATION<|>ORGANIZATION<|>The American Thyroid Association is a professional organization that provides guidelines for the management of thyroid conditions, including medullary thyroid carcinoma.)\n##\n(\"entity\"<|>MEDULLARY THYROID CARCINOMA<|>EVENT<|>Medullary thyroid carcinoma is a type of cancer that arises from the parafollicular cells of the thyroid and can be diagnosed and monitored using calcitonin levels.)\n##\n(\"entity\"<|>WELLS SA<|>PERSON<|>Wells SA is a researcher and author involved in the study and guidelines related to medullary thyroid carcinoma.)\n##\n(\"entity\"<|>TAC<|>EVENT<|>TAC refers to a type of imaging study used to evaluate the extent of disease in patients suspected of having medullary thyroid carcinoma.)\n##\n(\"entity\"<|>BETA BLOCKERS<|>EVENT<|>Beta blockers are a class of medications that are not associated with elevated calcitonin levels according to the text.)\n##\n(\"entity\"<|>HYPERGASTRINEMIA<|>EVENT<|>Hypergastrinemia is a condition that can lead to elevated calcitonin levels and is mentioned as a potential cause of increased calcitonin.)\n##\n(\"entity\"<|>RENAL INSUFFICIENCY<|>EVENT<|>Renal insufficiency is a condition that can also cause elevated calcitonin levels.)\n##\n(\"relationship\"<|>WELLS SA<|>AMERICAN THYROID ASSOCIATION<|>Wells SA is involved in the development of guidelines published by the American Thyroid Association regarding medullary thyroid carcinoma<|>7)\n##\n(\"relationship\"<|>MEDULLARY THYROID CARCINOMA<|>AMERICAN THYROID ASSOCIATION<|>The American Thyroid Association provides guidelines for the management of medullary thyroid carcinoma<|>8)\n##\n(\"relationship\"<|>MEDULLARY THYROID CARCINOMA<|>HYPERGASTRINEMIA<|>Hypergastrinemia is mentioned as a condition that can lead to elevated calcitonin levels, which is relevant in the context of medullary thyroid carcinoma<|>5)\n##\n(\"relationship\"<|>MEDULLARY THYROID CARCINOMA<|>RENAL INSUFFICIENCY<|>Renal insufficiency is mentioned as a condition that can lead to elevated calcitonin levels, which is relevant in the context of medullary thyroid carcinoma<|>5)\n##\n(\"relationship\"<|>BETA BLOCKERS<|>MEDULLARY THYROID CARCINOMA<|>Beta blockers are mentioned as not being associated with elevated calcitonin levels, which is relevant in the context of diagnosing medullary thyroid carcinoma<|>3)\n##\n(\"relationship\"<|>TAC<|>MEDULLARY THYROID CARCINOMA<|>TAC is a type of imaging study that may be used to evaluate the extent of medullary thyroid carcinoma<|>6)\n<|COMPLETE|>"}]}